At a glance
ClinicalIndex Comparison RecordN/ACompleted· 301 enrolled
Drug / intervention
Mirvaso® / Onreltea TMother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Mirvaso® Utilisation and Patient Satisfaction Evaluation
In Brief
An observational study evaluating Mirvaso® / Onreltea TM for Rosacea. Completed, enrolled 301 participants across 1 site.
Detailed Summary
The aim of the study is to evaluate the level of satisfaction among patients to whom Mirvaso® / Onreltea TM (trade mark) is prescribed.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsRosacea
CountriesCanada
CollaboratorsChiltern International Inc.
Timeline
N/ACompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartOct 2015
First PostedDec 2015
Primary CompletionMay 2016
TodayJul 2026
First PostedDec 22, 2015
Enrollment StartOct 1, 2015
Primary CompletionMay 1, 2016
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 10.5 years ago
Interventions
Mirvaso® / Onreltea TMother